Aif1 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
AIF1 (allograft inflammatory factor 1; IBA1) encodes a calcium-binding cytoskeletal adaptor that is strongly enriched in microglia. In neurodegenerative disease research, AIF1 is used as a core readout for microglial recruitment, morphology, and activation state around pathology such as amyloid-beta, tau, and alpha-synuclein.[1][2]
| Gene Symbol | AIF1 |
|---|---|
| Full Name | Allograft Inflammatory Factor 1 |
| Common Alias | IBA1 |
| Chromosomal Location | 6p21.3 |
| NCBI Gene ID | 199 |
| Ensembl ID | ENSG00000240065 |
| UniProt ID | P55072 |
| Primary Cell Context | Microglia and infiltrating myeloid cells |
AIF1 is an EF-hand calcium-binding protein that couples inflammatory signaling to actin remodeling. In activated microglia it supports membrane ruffling, process extension/retraction, migration toward chemotactic signals, and phagocytic cup formation.[1:1][3] Because these behaviors are central to tissue surveillance and debris clearance, AIF1 expression generally rises as microglia transition from homeostatic states to injury- or disease-responsive states.[2:1][4]
Key functional themes include:
In Alzheimer's disease, AIF1-positive microglia accumulate around plaques and dystrophic neurites, where they can provide both protective and harmful effects depending on timing and state.[2:3][5] Early responses may support compaction/containment of amyloid deposits, but chronic inflammatory signaling is associated with synaptic stress and network dysfunction.[5:1][6]
AIF1 staining is therefore interpreted together with disease-stage markers and signaling pathways such as NLRP3 inflammasome, NF-kB, and microglia-neuroinflammation.
In Parkinson's disease, AIF1-positive microglia are increased in vulnerable regions including substantia nigra.[7] Interaction with neuronal alpha-synuclein species can amplify cytokine signaling and oxidative stress programs that contribute to dopaminergic vulnerability.[7:1][8]
In amyotrophic lateral sclerosis, elevated AIF1 signal is commonly observed in spinal and corticospinal compartments and tracks with myeloid activation around degenerating motor units.[9] Similar patterns are reported across frontotemporal and multisystem neurodegenerative syndromes with strong neuroimmune components.[5:2][9:1]
AIF1 can be placed in a practical mechanistic chain:
This framing links AIF1 to broader pathways in selective neuronal vulnerability, oxidative stress, and complement-mediated-synapse-loss.
AIF1 is primarily a tissue-level and imaging-adjacent marker rather than a standalone circulating diagnostic biomarker. Its translational value is strongest when integrated with multimodal readouts:
Aif1 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Aif1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
AIF1 is often treated as a binary marker of "activated" microglia, but modern single-cell and spatial profiling shows that AIF1-high cells span multiple states with different functional consequences.[2:5][4:4] In practice, interpretation should be paired with state-defining markers (for example, lipid-handling, interferon-response, and antigen-presentation modules), regional context, and pathology stage.[4:5][6:2]
Preclinical studies commonly combine AIF1 immunoreactivity with readouts of autophagy, synaptic density, and complement deposition to distinguish whether interventions shift microglia toward clearance-supportive versus injury-amplifying programs.[5:5][6:3] This is especially relevant for trials targeting TREM2 therapeutics, NLRP3 inflammasome, or cytokine cascades, where preserving beneficial debris handling is a major translational constraint.[5:6][9:2]
Imai Y, Ibata I, Ito D, Ohsawa K, Kohsaka S. A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem Biophys Res Commun. 1996. ↩︎ ↩︎
Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer's disease. Cell. 2017. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Ohsawa K, Imai Y, Sasaki Y, Kohsaka S. Microglia/macrophage-specific protein Iba1 binds to fimbrin and enhances its actin-bundling activity. J Neurochem. 2001. ↩︎
Krasemann S, Madore C, Cialic R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Heneka MT, Carson MJ, El Khoury J, et al. [Neuroinflammation in Alzheimer's disease](https://doi.org/10.1016/S1474-4422(15). Lancet Neurol. 2015. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Neurol. 2018. ↩︎ ↩︎ ↩︎ ↩︎
Hirsch EC, Hunot S. [Neuroinflammation in Parkinson's disease: a target for neuroprotection?](https://doi.org/10.1016/S1471-1931(09). Lancet Neurol. 1931. ↩︎ ↩︎
Pajares M, Rojo AI, Manda G, Bosca L, Cuadrado A. Inflammation in Parkinson's disease: mechanisms and therapeutic implications. Cell Signal. 2019. ↩︎
Geloso MC, Corvino V, Marchese E, Serrano A, Michetti F, D'Ambrosi N. The dual role of microglia in ALS: mechanisms and therapeutic approaches. Front Aging Neurosci. 2017. ↩︎ ↩︎ ↩︎